Matthew D. Rotelli
Eli Lilly (United States) · 15 works · 400 citations · h-index 8
Top works
- Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders
- Nitrate removal in riparian wetland soils: Effects of flow rate, temperature, nitrate concentration and soil depth
- Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia
- Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach
- Flexible-Dose Clinical Trials
- Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: Post hoc analysis of patients treated with olanzapine or lithium
- A New Model for Communicating Risk Information in Direct-to-Consumer Print Advertisements
- Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches
- Ethical Considerations for Increased Transparency and Reproducibility in the Retrospective Analysis of Health Care Data
- Cardiovascular Drug Development: Protocol Design and Methodology
- Neural networks as a tool for statistical modeling
- Panel discussion 1
- Response to “Statistical Thinking and Methods in Quality Improvement: A Look to the Future” by Roger Hoerl and Ronald Snee
- Response to “Statistical Thinking and Methods in Quality Improvement: A Look to the Future”
- Panel discussion 2